AKAP1 and cardiac hypertrophy: It is possible to speculate that cardiac hypertrophy requires a prolonged treatment with D-AKAP1 displacing peptides or that ‘delocalized’ pools of D-AKAP1 in vivo might still bind and sequester calcineurin, thus preventing the activation of the NFAT-dependent hypertrophic gene program.